Today: 13 June 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Exxon Mobil stock faces Monday test as Trump pitches Venezuela oil rebuild for U.S. giants

Exxon Mobil stock faces Monday test as Trump pitches Venezuela oil rebuild for U.S. giants

Exxon Mobil shares rose 1.9% Friday after President Trump said U.S. oil companies are prepared to invest billions in Venezuela’s oil sector following Nicolás Maduro’s capture by U.S. forces. Analysts warned repairs could take years and the U.S. embargo remains in place. Brent crude ended down 0.7% at $60.33 a barrel. Investors are watching for Venezuela policy updates and U.S. jobs data due Jan. 9.
5 January 2026
···
Indore water crisis widens to nerve-disorder fears as Mangaluru clears chargers for 100 e-buses

Indore water crisis widens to nerve-disorder fears as Mangaluru clears chargers for 100 e-buses

Indore officials confirmed six deaths in a diarrhoea outbreak linked to contaminated water, while residents claimed 16. Doctors reported a 67-year-old patient with symptoms of Guillain-Barre syndrome, but officials have not confirmed a link to the outbreak. Health teams have screened over 9,400 people, with 398 hospital admissions so far. A national research team has joined the response.
4 January 2026
Asana stock slides 5% to start 2026 — downgrade and key dates that could move ASAN next

Asana stock slides 5% to start 2026 — downgrade and key dates that could move ASAN next

Asana shares fell 5.4% to $12.96 Friday after Wall Street Zen downgraded the stock to “hold,” MarketBeat reported. The drop leaves Asana near its 52-week low, with investors watching for signs of further U.S. rate cuts after Fed officials signaled patience. The S&P 500 rose 0.2% while the Nasdaq-100 slipped 0.2%. Asana last forecast Q4 revenue of $204 million to $206 million.
4 January 2026
··
ZoomInfo stock slides 5.5% — key levels and the next dates investors are watching

ZoomInfo stock slides 5.5% — key levels and the next dates investors are watching

ZoomInfo shares fell 5.5% to $9.61 on Friday, closing below both the 50-day and 200-day moving averages. Trading volume rose to 5.83 million shares, up from 4.24 million on Dec. 31. Investors are watching for the next U.S. jobs report and the company’s upcoming earnings window. ZoomInfo last reported Q3 revenue of $318 million and guided Q4 revenue to $307–310 million.
4 January 2026
·
Palantir (PLTR) stock slides 5.6% as insider sale notice surfaces — what to watch next week

Palantir (PLTR) stock slides 5.6% as insider sale notice surfaces — what to watch next week

Palantir shares fell 5.6% to $167.86 Friday, their first 2026 session, after an SEC filing showed officer Ryan D. Taylor plans to sell up to 12,000 shares under a 10b5-1 plan. The stock swung from an early high near $183 to a low around $166. Markets reopen Monday with U.S. jobs and inflation data due next week. Palantir’s next earnings report is expected in early February.
4 January 2026
·
Establishment Labs (ESTA) stock drops 5.5% — what to watch before Monday’s open and JPM conference

Establishment Labs (ESTA) stock drops 5.5% — what to watch before Monday’s open and JPM conference

Establishment Labs shares fell 5.5% to $68.84 Friday, underperforming a flat Nasdaq. The company recently submitted its Motiva implants to the FDA for breast reconstruction approval. Management will present at the J.P. Morgan Healthcare Conference on Jan. 14. Establishment Labs posted a 2024 net loss of about $85 million on $166 million in revenue.
4 January 2026
··
Via Transportation stock sinks to 52-week low territory after 6% Friday slide — what to watch next for NYSE:VIA

Via Transportation stock sinks to 52-week low territory after 6% Friday slide — what to watch next for NYSE:VIA

Via Transportation shares fell 6.3% Friday to $27.18, near their 52-week low and about 41% below the company’s $46 IPO price from September. The drop came as the S&P 500 rose and mobility peers Uber and Lyft gained. Investors await key U.S. jobs and inflation data next week. Via remains unprofitable and faces risks from public-sector spending and regulatory challenges.
4 January 2026
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences shares fell 6.2% to $15.95 Friday, underperforming the flat Nasdaq Biotechnology Index. The company expects more Phase 1 obesity trial data in Q1 2026. A December SEC filing said Wave’s equity raise, including over-allotments, was expected to bring in about $402.5 million. Early data showed WVE-007 reduced visceral fat by 9.4% at three months in a 32-person cohort.
4 January 2026
·
Exzeo Group (XZO) stock drops 6% into weekend — what investors are watching next

Exzeo Group (XZO) stock drops 6% into weekend — what investors are watching next

Exzeo shares fell 6.1% to $22.76 Friday, with trading volume jumping to 424,000 shares from 240,000 the previous session. The stock touched a low of $22.19 and a high of $24.49 during the day. Exzeo’s next earnings report is due Feb. 25. HCI Group, which owns 81.5% of Exzeo, disclosed its CEO Paresh Patel adopted a plan to buy up to 100,000 shares if prices drop further.
4 January 2026
1 … 313 314 315 316 317 … 590

Stock Market Today

  • Morningstar-CME License Deal Expands Derivatives Amid Share Price Pressure
    June 13, 2026, 3:45 PM EDT. Morningstar has forged a multi-year licensing deal with CME Group to list futures and options based on Morningstar equity index benchmarks. The new agreement allows investors to access Morningstar Market Indexes, which underpin over US$3 billion in assets, via listed derivatives, increasing their utility for asset managers and traders. Despite this, Morningstar's stock (NasdaqGS:MORN) has faced significant pressure, down 16.7% year-to-date and 40.9% over 12 months, reflecting broader challenges. The deal positions Morningstar alongside index heavyweights S&P Global and MSCI but carries risks including contract execution risk if CME's products fail to gain traction, and concerns over debt and insider selling. The move highlights Morningstar's strategy to deepen monetization of its intellectual property beyond data subscriptions.

Latest articles

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

13 June 2026
KLA soared 5.55% to $254.54 on its first split-adjusted day after a 10-for-1 stock split and analyst price target hikes tied to AI-driven chip equipment demand, but with the stock now above several split-adjusted targets, investors face heightened risk ahead of the fiscal Q4 report, which will be the next key catalyst for revenue, earnings, and AI-linked demand guidance.
Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer trades around $26 with dividend in focus, drug-price worries linger

13 June 2026
Pfizer closed at $26.21, up 0.15%, outperforming the Health Care Select Sector SPDR ETF despite new German drug-pricing pressures and a European legal setback; investors are focused on the 6.56% dividend yield, reaffirmed 2026 guidance, and pipeline progress in obesity and oncology as Q2 earnings on August 4 approach.
Go toTop